SAMSUNG BIOLOGICS Co., Ltd. (207940)
Korea Exchange · Health Technology
SAMSUNG BIOLOGICS Co., Ltd stock (207940): its screening is incomplete: the source lacks data, per our screen under AAOIFI Shari'ah Standard No. 21 dated 2026-10-25.
- Price
- 1,466,000 KRWLast close 2026-10-23
- Market cap
- 70.53 T KRWat the 2026-10-23 close
- Symbol
- KRX:207940
- Market
- Korea Exchange
- Sector
- Health Technology
- Industry
- Biotechnology
Identity page only: this company is inside our coverage, but its fundamental figures are incomplete at the source, so it enters no scoring and no ranking.
Figures as of 2026-10-25 04:08
Sharia screening
Screening did not complete: company data missing at the source
We apply AAOIFI Shari'ah Standard No. 21, Financial Paper (Shares and Bonds), issued on 30 Rabi' I 1425 AH (20 May 2004), as published on AAOIFI's website. We last reviewed its limits on 2026-10-01. We read what the standard says; we do not issue fatwas.
This is an automated read of published screens, not a fatwa. We name what we ran; whatever we did not run stays outside the read.
We receive the ticker only, with no account and no email.
The screening of SAMSUNG BIOLOGICS Co., Ltd. is not complete yet. The Sharia results for every stock on Korea Exchange are in one free list. Open the free list
SAMSUNG BIOLOGICS Co., Ltd in numbers
SAMSUNG BIOLOGICS Co., Ltd is the largest company in the Health Technology sector on Korea Exchange, with a market cap of 70.53 T KRW.
Published figures with their date, not financial advice. Market cap and P/E use the 2026-10-23 close.
The five screens, one by one
No score: the screen did not complete
No score: the screen did not complete
We ran 2 of 5 screens; the score did not complete because company data is missing at the source.
| Business activity (sector and industry) | No excluded activity in its sector or industry | Passed |
| Interest-bearing debt to market cap | limit 30% | Not measured: figure missing at the source |
| Cash and interest-bearing securities to market cap | limit 30% | Not measured: figure missing at the source |
| Non-permissible income to revenue | 1%, limit 5% | Passed |
| Receivables to market cap | Not run: the standard sets no limit for it |
Purification share
We do not publish a per-share purification amount yet. The non-permissible income share appears on the 5% line when we measure it, and when we do not, we do not guess a figure.
Figures as of 2026-10-25 04:08
Fundamental filter
Meets the filter, with stated notes
- The company actually earned a profit over the last twelve months. Met
- Its debt does not exceed twice its shareholders' equity. Not measured
Figures as of 2026-10-25
An automated quality screen on published figures, not financial advice. Every threshold is stated, every reason is named with its figure and its date, and the decision stays yours.
Frequently asked about SAMSUNG BIOLOGICS Co., Ltd
What is the sharia compliance score of SAMSUNG BIOLOGICS Co., Ltd?
SAMSUNG BIOLOGICS Co., Ltd: No score: the screen did not complete. The score out of 100 measures how far the debt and cash ratios sit from their stated limits; the five screens are broken down on this page.
Does SAMSUNG BIOLOGICS Co., Ltd stock need purification?
We do not publish a per-share purification amount yet. The non-permissible income share appears on the 5% line when we measure it, and when we do not, we do not guess a figure.
How do I work out zakat on SAMSUNG BIOLOGICS Co., Ltd shares?
The zakat calculator on this site gives an indicative amount from the value of the shares you hold; detailed rulings belong to scholars.
Which market lists SAMSUNG BIOLOGICS Co., Ltd?
SAMSUNG BIOLOGICS Co., Ltd is listed on Korea Exchange under the symbol 207940.
Latest news on the company
- Samsung Bioepis Releases Fourth Quarter 2026 Biosimilar Market Report Highlighting Importance of Supply ContinuityBusinessWire ·
- Samsung Biologics : Revenue grew 18.5% as FY26 growth guidance rose to 20%Quartr ·
- Samsung Biologics Co., Ltd. Q3 Rev KRW 1.49T; Lifts 2026 Growth Guide to 20%TradingView ·
- Samsung Epis Holdings Says Unit Samsung Bioepis Entered Into Exclusive Supply Agreement Under Brazilian Government Programme For Rare-Disease TreatmentReuters ·
- Polypeptide Group Definitive Interim Result Of The Public Tender Offer Of Samsung BiologicsReuters ·
News from its original sources; the reading is in your account.